Document is current

Article History

Received: 28 March 2024

Accepted: 28 March 2025

First Online: 4 August 2025

Declarations

:

: This study was submitted and approved by local and central Ethics Committees in France (Comité de Protection de Personnes Sud-Ouest & Outre-Mer IV), Belgium (Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège), Italy (Comitato Etico dell’Universita SAPIENZA and dell’Universita Campus Bio-Medico Di Roma) and the US (Western Institutional Review Board-Copernicus group and Columbia University Institutional Review Board 2). We certify that this study has received approvals from the appropriate ethical committees as described above. Written informed consent were obtained from the patient or legal authorized representative.

: Not applicable.

: RAF reports grant support from Lonza, Biophytis, National Institutes of Health, and USDA, scientific advisory board membership for Biophytis, Amazentis, Inside Tracker, Rejuventate Biomed, Aging in Motion, consultancies for Embion, Biophytis, Amazentis, Pfizer, Nestle, Rejuvenate Biomed.YR reports support from CHU Toulouse, University Paul Sabatier and INSERM CERPOP1295 (employee), to be a shareholder of SARQOL SPRL, a spin-off of the University of Liege, consultancy fees from Longeveron, to be a Scientific Advisory Board member to Biophytis, and have received honoraria for lectures for Pfizer.OB reports to be stakeholder of SARQOL SRL, a spin off of the University of Liege in charge of the interest of the SarQoL and reports consulting or lecture fees (in the last 5 years) from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris.CT, RVM, SV and WD are employees of Biophytis SA.JM is the President of the Scientific Advisory Board of Biophytis SA.CM and SDS are former employees of Biophytis.AT, LMD, MB, MD, MR, RAI declare that they have no competing interests.YR reports support from CHU Toulouse, University Paul Sabatier and INSERM CERPOP1295 (employee), to be a shareholder of SARQOL SPRL, a spin-off of the University of Liege, consultancy fees from Longeveron, to be a Scientific Advisory Board member to Biophytis, and have received honoraria for lectures for Pfizer.OB reports to be stakeholder of SARQOL SRL, a spin off of the University of Liege in charge of the interest of the SarQoL and reports consulting or lecture fees (in the last 5 years) from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris. CT, RVM, SV and WD are employees of Biophytis SA.JM is the President of the Scientific Advisory Board of Biophytis SA.CM and SDS are former employees of Biophytis.AT, LMD, MB, MD, MR, RAI declare that they have no competing interests.